Fidelity Investments
STSA

Fidelity Investments’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Fidelity Investments’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-45
Closed -$41 – 5611
2022
Q4 		$41 Buy
+45
New +$130 ﹤0.01% 4982
2022
Q2 		– Sell
-2,163
Closed -$8K – 5668
2022
Q1 		$8K Buy
+2,163
New +$9.75K ﹤0.01% 4319

Other funds holding STSA

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Fidelity Investments's STSA Position: Q1 2023 in Review

Fidelity Investments sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q1 2023, closing a stake of 45 shares — an estimated $41 sold.

Fidelity Investments first reported a position in STSA in Q1 2022 and held it in 2 quarters. The position peaked at $8K in Q1 2022. 31 funds tracked by Wall St. Rank hold STSA as of Q1 2023.

  • Fidelity Investments reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Fidelity Investments sold 45 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $41.
  • Fidelity Investments first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Fidelity Investments's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $8K in Q1 2022.
  • 31 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Fidelity Investments's 13F filing for Q1 2023, filed 11 May 2023.